
OrthoPediatrics (KIDS) Stock Forecast & Price Target
OrthoPediatrics (KIDS) Analyst Ratings
Bulls say
OrthoPediatrics Corp has demonstrated significant growth, with Trauma & Deformity sales increasing by 17.3% year-over-year to $44.1 million, reflecting robust market demand that exceeded estimates. Additionally, the company achieved a strong adjusted EBITDA margin improvement of 280 basis points year-over-year, signaling enhanced operational efficiency. Management's confidence in revenue growth, driven by potential upswings in distributive productivity and product uptake, sets a positive long-term outlook for the company's financial performance.
Bears say
The analysis indicates several fundamental concerns regarding OrthoPediatrics Corp's stock, particularly highlighting a slowdown in revenue growth, which declined to 12.2% in the third quarter of 2025 from 15.7% in the previous quarter. Additionally, the company's recent deployment of product sets decreased from $17.2 million to $16.0 million over the trailing twelve months, further signaling weaker sales performance. Coupled with lowered fiscal year 2025 revenue guidance of $233.5 million to $234.5 million, these factors collectively contribute to a more pessimistic outlook due to potential challenges in product launches and productivity gains among distributors.
This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.
OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction
Start investing in OrthoPediatrics (KIDS)
Order type
Buy in
Order amount
Est. shares
0 shares